Centessa Pharmaceuticals PLC
CNTA25.680USD
+0.420+1.66%
Close 12/24, 16:00（ET）Quotes delayed by 15 min
3.45BMarket Cap
LossP/E TTM
More Details of Centessa Pharmaceuticals PLC Company
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Centessa Pharmaceuticals PLC Info
Ticker SymbolCNTA
Company nameCentessa Pharmaceuticals PLC
IPO dateMay 28, 2021
CEOSaha (Saurabh)
Number of employees77
Security typeDepository Receipt
Fiscal year-endMay 28
Address3rd Floor
CityALTRINCHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeWA14 2DT
Phone447391789784
Websitehttps://www.centessa.com/
Ticker SymbolCNTA
IPO dateMay 28, 2021
CEOSaha (Saurabh)
Company Executives of Centessa Pharmaceuticals PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
60.24K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Dr. Stephen J. Kanes, M.D., Ph.D.
Dr. Stephen J. Kanes, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kristen K. Sheppard, Esq.
Mr. Kristen K. Sheppard, Esq.
Senior Vice President Investor Relations
Senior Vice President Investor Relations
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Crowley
Mr. John Crowley
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen Anderson
Ms. Karen Anderson
Chief People Officer
Chief People Officer
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mary Lynne Hedley, Ph.D.
Dr. Mary Lynne Hedley, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
60.24K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Dr. Stephen J. Kanes, M.D., Ph.D.
Dr. Stephen J. Kanes, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kristen K. Sheppard, Esq.
Mr. Kristen K. Sheppard, Esq.
Senior Vice President Investor Relations
Senior Vice President Investor Relations
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Crowley
Mr. John Crowley
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Medicxi Ventures (UK) LLP
13.67%
Avoro Capital Advisors LLC
7.40%
Adage Capital Management, L.P.
6.87%
Index Ventures SA
6.82%
General Atlantic LLC
5.04%
Other
60.19%
Shareholders
Shareholders
Proportion
Medicxi Ventures (UK) LLP
13.67%
Avoro Capital Advisors LLC
7.40%
Adage Capital Management, L.P.
6.87%
Index Ventures SA
6.82%
General Atlantic LLC
5.04%
Other
60.19%
Shareholder Types
Shareholders
Proportion
Venture Capital
21.32%
Investment Advisor/Hedge Fund
20.16%
Hedge Fund
19.36%
Investment Advisor
17.12%
Private Equity
8.07%
Research Firm
1.42%
Individual Investor
0.39%
Pension Fund
0.01%
Other
12.16%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
239
133.92M
99.37%
+16.61K
2025Q3
241
133.90M
109.10%
+4.79M
2025Q2
226
132.04M
110.14%
-1.07M
2025Q1
214
132.76M
108.57%
-12.24M
2024Q4
180
128.06M
101.80%
+5.92M
2024Q3
158
122.07M
88.34%
+22.15M
2024Q2
135
99.90M
89.43%
+12.17M
2024Q1
129
87.74M
96.45%
-9.01M
2023Q4
114
84.27M
95.12%
+1.65M
2023Q3
113
82.62M
96.02%
+2.24M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Medicxi Ventures (UK) LLP
19.96M
14.89%
--
--
Jun 30, 2025
Avoro Capital Advisors LLC
5.00M
3.73%
+950.00K
+23.46%
Jun 30, 2025
Adage Capital Management, L.P.
8.40M
6.27%
+1.45M
+20.84%
Jun 30, 2025
Index Ventures SA
9.96M
7.43%
--
--
Jun 30, 2025
General Atlantic LLC
9.68M
7.22%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
3.83M
2.85%
--
--
Jun 30, 2025
Janus Henderson Investors
6.53M
4.87%
+610.28K
+10.30%
Jun 30, 2025
T. Rowe Price Associates, Inc.
5.91M
4.41%
+565.65K
+10.59%
Jun 30, 2025
Farallon Capital Management, L.L.C.
4.53M
3.38%
+195.00K
+4.50%
Jun 30, 2025
VV Manager LLC
3.93M
2.95%
--
--
Dec 31, 2024
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
3.56%
Virtus LifeSci Biotech Clinical Trials ETF
1.4%
Invesco Nasdaq Biotechnology ETF
0.23%
ProShares Ultra Nasdaq Biotechnology
0.23%
T Rowe Price Small-Mid Cap ETF
0.15%
iShares Biotechnology ETF
0.13%
Fidelity Fundamental Small-Mid Cap ETF
0.11%
iShares Intl Small Cap Equity Factor ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
SPDR S&P International Small Cap ETF
0%
View more
iShares Neuroscience and Healthcare ETF
Proportion3.56%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.4%
Invesco Nasdaq Biotechnology ETF
Proportion0.23%
ProShares Ultra Nasdaq Biotechnology
Proportion0.23%
T Rowe Price Small-Mid Cap ETF
Proportion0.15%
iShares Biotechnology ETF
Proportion0.13%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.11%
iShares Intl Small Cap Equity Factor ETF
Proportion0.01%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
SPDR S&P International Small Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Centessa Pharmaceuticals PLC?
The top five shareholders of Centessa Pharmaceuticals PLC are:
Medicxi Ventures (UK) LLP holds 19.96M shares, accounting for 14.89% of the total shares.
Avoro Capital Advisors LLC holds 5.00M shares, accounting for 3.73% of the total shares.
Adage Capital Management, L.P. holds 8.40M shares, accounting for 6.27% of the total shares.
Index Ventures SA holds 9.96M shares, accounting for 7.43% of the total shares.
General Atlantic LLC holds 9.68M shares, accounting for 7.22% of the total shares.
Medicxi Ventures (UK) LLP holds 19.96M shares, accounting for 14.89% of the total shares.
Avoro Capital Advisors LLC holds 5.00M shares, accounting for 3.73% of the total shares.
Adage Capital Management, L.P. holds 8.40M shares, accounting for 6.27% of the total shares.
Index Ventures SA holds 9.96M shares, accounting for 7.43% of the total shares.
General Atlantic LLC holds 9.68M shares, accounting for 7.22% of the total shares.
What are the top three shareholder types of Centessa Pharmaceuticals PLC?
The top three shareholder types of Centessa Pharmaceuticals PLC are:
Medicxi Ventures (UK) LLP
Avoro Capital Advisors LLC
Adage Capital Management, L.P.
Medicxi Ventures (UK) LLP
Avoro Capital Advisors LLC
Adage Capital Management, L.P.
How many institutions hold shares of Centessa Pharmaceuticals PLC (CNTA)?
As of 2025Q4, 239 institutions hold shares of Centessa Pharmaceuticals PLC, with a combined market value of approximately 133.92M, accounting for 99.37% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -9.73%.
What is the biggest source of revenue for Centessa Pharmaceuticals PLC?
In --, the -- business generated the highest revenue for Centessa Pharmaceuticals PLC, amounting to -- and accounting for --% of total revenue.
